Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?

Assessment of the Use of Therapeutic Drug Monitoring of Adalimumab on Maintenance Therapy in Children with Inflammatory Bowel Disease

(2017) Mallory Chavannes et al.   GASTROENTEROLOGY

Machine Learning Models at Week 6 of Vedolizumab Therapy for Ulcerative Colitis can Accurately Predict Week 52 Corticosteroid Free Endoscopic Remission

(2017) Akbar K. Waljee et al.   GASTROENTEROLOGY

Proactive Monitoring of Infliximab (IFX) and Adalimumab (ADA) Drug and Anti-Drug Antibody Concentration Utilizing the Labcorp Assay in Inflammatory Bowel Disease (IBD) Patients

(2017) Rajiv A. Perinbasekar et al.   GASTROENTEROLOGY

Higher Vedolizumab Levels are Associated with Deep Remission in Patients with Crohn's Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab

(2017) Andres J. Yarur et al.   GASTROENTEROLOGY

Serum Adalimumab Trough Levels Required for Endoscopic Mucosal Healing during Maintenance Therapy of Crohn's Disease

(2017) Hirotsugu Imaeda et al.   GASTROENTEROLOGY

Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) During Maintenance Therapy

(2017) Ryan C. Ungaro et al.   GASTROENTEROLOGY

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

(2017) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

(2017) Mariam Aguas Peris et al.   INFLAMMATORY BOWEL DISEASES

Can We Predict the Efficacy of Anti-TNF-α Agents?

(2017) Loris Lopetuso et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn’s disease

(2017) Chuanpu Hu et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

(2017) Catharine C. Bulik et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Landmark and longitudinal exposure–response analyses in drug development

(2017) Chuanpu Hu et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Novel Targeted Therapies for Inflammatory Bowel Disease

(2017) Mehmet Coskun et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases

(2016) Dario Sorrentino et al.   INFLAMMATORY BOWEL DISEASES

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies

(2016) Omoniyi J. Adedokun et al.   Journal of Crohns & Colitis

Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review

(2016) Laura Martelli et al.   JOURNAL OF GASTROENTEROLOGY

Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes

(2016) Siddharth Singh et al.   Nature Reviews Gastroenterology & Hepatology

Abnormal laboratory results: Therapeutic drug monitoring: which drugs, why, when and how to do it

(2016) RA Ghiculesco   Australian Prescriber

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

(2015) M. Rosario et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics of adalimumab in Crohn’s disease

(2015) David Ternant et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn's Disease Patients

(2015) Maria Chaparro et al.   GASTROENTEROLOGY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial

(2015) Filip Baert et al.   GUT

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

(2015) Andres J Yarur et al.   GUT

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

(2015) Janet R. Wade et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up

(2015) Der-Yuan Chen et al.   RHEUMATOLOGY

565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD)

(2015) Brian G. Feagan et al.   GASTROENTEROLOGY

Sa2044 Decrease in Serum Infliximab Level Precedes Loss of Clinical Response and Can Be Easily Detected by the Elevation of C-Reactive Protein in Crohn's Disease

(2015) Toshifumi Hibi et al.   GASTROENTEROLOGY

Sa2047 Association of Serum Infliximab and Antibodies to Infliximab to Long-Term Clinical Outcome in Acute Ulcerative Colitis

(2015) Sanjay Murthy et al.   GASTROENTEROLOGY

Tu1147 Serum Adalimumab Levels and Antibodies Correlate With Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients With Inflammatory Bowel Disease

(2015) Andres J. Yarur et al.   GASTROENTEROLOGY

490 Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between Ata and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients

(2015) Fernando S. Velayos et al.   GASTROENTEROLOGY

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

(2014) Y. Mazor et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Sa1264 Drug Trough Levels and Primary Nonresponse to antiTNF Therapy in Moderate-Severe Crohn Disease. Results of the Optimiza Study

(2014) Ana Echarri et al.   GASTROENTEROLOGY

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

One Mouse, One Pharmacokinetic Profile: Quantitative Whole Blood Serial Sampling for Biotherapeutics

(2014) Alison P. Joyce et al.   PHARMACEUTICAL RESEARCH

Clinical and genetic factors predicting response to therapy in patients with Crohn’s disease

(2014) Marilia Cravo et al.   United European Gastroenterology Journal

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Key findings towards optimising adalimumab treatment: the concentration–effect curve

(2013) Mieke F Pouw et al.   ANNALS OF THE RHEUMATIC DISEASES

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis

(2013) Bart J. F. van den Bemt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab

(2013) Fernando S. Velayos et al.   Clinical Gastroenterology and Hepatology

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2013) Xavier Roblin et al.   Clinical Gastroenterology and Hepatology

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

(2013) Casper Steenholdt et al.   GUT

High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment

(2013) Fernando Magro et al.   Journal of Crohns & Colitis

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease

(2012) Ingrid Ordás et al.   Clinical Gastroenterology and Hepatology

P334 Concentration effect relationship of infliximab in Crohn's disease: Results of a cohort study

(2012) C. Lamblin et al.   Journal of Crohns & Colitis

OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis

(2012) M.T. Arias et al.   Journal of Crohns & Colitis

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

(2012) Martin Bortlik et al.   Journal of Crohns & Colitis

Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

(2012) Hidetoshi Takahashi et al.   JOURNAL OF DERMATOLOGY

Safe and Effective Variability—A Criterion for Dose Individualization

(2012) Nicholas H.G. Holford et al.   THERAPEUTIC DRUG MONITORING

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

(2011) Emilie Ducourau et al.   ARTHRITIS RESEARCH & THERAPY

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

(2010) Hideshi Torii et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

(2010) Casper Steenholdt et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Overview of Therapeutic Drug Monitoring

(2009) Ju-Seop Kang et al.   KOREAN JOURNAL OF INTERNAL MEDICINE